Astera Labs (ALAB) will likely benefit partly from new product offerings and industry spending on artificial intelligence projects, Morgan Stanley said Monday in a report. Monday.
"Astera offers one of the best growth rates in our coverage, with multiple product cycles and a very strong position in key AI technology -- with visibility into multiple product cycles that have yet to even start to ramp," the report said. "We like the growth story, and valuation is attractive at this level."
Morgan Stanley upgraded Astera's stock to overweight from equal weight and kept the price target at $99.
"We strongly disagree with the concerns over possible AI digestion this year and believe there is too much pessimism," the report said. Astera "should continue to see strong growth across their multiple product families, which span the entire rack across all the major protocols," Morgan Stanley said.
Astera shares jumped 9.6% in recent trading Monday.
Price: 78.05, Change: +6.85, Percent Change: +9.62
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.